<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02397603</url>
  </required_header>
  <id_info>
    <org_study_id>N-16-2015</org_study_id>
    <nct_id>NCT02397603</nct_id>
  </id_info>
  <brief_title>Peri-neural Dexmedetomidine as an Adjuvant to Bupivacaine Induced Paravertebral Block in Patients Undergonig Thoracotomy</brief_title>
  <official_title>Peri-neural Dexmedetomidine as an Adjuvant to Bupivacaine-induced Paravertebral Block in Patients Undergoing Thoracotomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the effect of adding dexmedetomidine as an adjuvant to bupivacaine in
      patients undergoing thoracotomy when administered peri-neurally in thoracic paravertebral
      space.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Thoracotomy is associated with severe postoperative pain that could be reduced with an
      aggressive analgesic therapy in the early postoperative period. The use of thoracic
      paravertebral block is an effective analgesic approach for post-thoracotomy pain. Several
      local anesthetic adjuvants have been reported to extend the duration of paravertebral block.

      Alpha-2 agonists including dexmedetomidine appear to be the most effective in this context.
      The study will include an intervention group which will receive a combination of 20 ml
      bupivacaine 0.5% and dexmedetomidine 0.5 ml (50 microgram). The control group will receive 20
      ml bupivacaine 0.5% plus 0.5 ml normal saline perineurally. Thoracic paravertebral catheter
      will be inserted preoperatively. Visual analogue pain score will be assessed at different
      intervals.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of first loading preoperative dose of paravertebral injectate</measure>
    <time_frame>One day</time_frame>
    <description>Time interval between initiation of the paravertebral block and the time to first rescue analgesia</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of surgery and anesthesia</measure>
    <time_frame>Intraoperative period, up to 3-4 hours</time_frame>
    <description>Times from start of anesthesia and surgery to the conclusion of surgical intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>End tidal isoflurane</measure>
    <time_frame>Duration of anesthesia, up to 3-4 hours</time_frame>
    <description>Average End-tidal isoflurane concentration required to maintain stable hemodynamics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total intraoperative fentanyl requirements</measure>
    <time_frame>Intraoperative period, up to 3-4 hours</time_frame>
    <description>The total dose of fentanyl required during the surgical procedure to maintain hemodynamic stability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total intraoperative ephedrine and atropine requirements</measure>
    <time_frame>Intraoperative period, up to 3-4 hours</time_frame>
    <description>The total amounts of ephidrine and atropine required for the treatment of possible reduction of arterial blood pressure or heart rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total intraoperative crystalloid requirements</measure>
    <time_frame>Intraoperative period, up to 3-4 hours</time_frame>
    <description>The total volume of intraoperative fluids in ml required to maintain hemodynamic stability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recovery time</measure>
    <time_frame>Immediate postoperative period, up to 2 hour</time_frame>
    <description>the time interval between discontinuation of isoflurane and the patient first response to verbal commands</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain intensities at rest and during coughing as assessed by 0-10 VAS score</measure>
    <time_frame>Over 48 hours postoperatively</time_frame>
    <description>Pain scores will be assessed using the 11-points visual analogue pain score (VAS) where 0 indicates no pain and 10 indicates the worst pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total doses of bupivacaine, dexmedetomidine, and morphine</measure>
    <time_frame>48 hours postoperatively</time_frame>
    <description>The total doses of three medications will be recorded and compared in the intervention and control groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of paravertebral to-up injections</measure>
    <time_frame>48 hours postoperatively</time_frame>
    <description>The number of to-up doses of bupivacaine required to maintain adequate postoperative analgesia over 48 hours postoperatively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects</measure>
    <time_frame>48 hours postoperatively</time_frame>
    <description>Patients will be monitored for the possible reductions in arterial blood pressure and heart rate</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Acute Post-thoracotomy Pain</condition>
  <arm_group>
    <arm_group_label>bupivacaine saline group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group of patients will receive 20 ml bupivacaine plus 0.5 ml normal saline perineurally in the paravertebral catheter</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexmedetomidine- bupivacaine group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group of patients will receive 20 ml bupivacaine plus 0.5 ml (50 microgram) dexmedetomidine administered perineurally in the paravertebral catheter.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexmedetomidine bupivacaine</intervention_name>
    <description>perineural dexmedetomidine as an adjuvant to bupivacaine induced thoracic paravertebral block</description>
    <arm_group_label>Dexmedetomidine- bupivacaine group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine saline</intervention_name>
    <description>perineural bupivacaine saline mixture in the thoracic paravertebral catheter</description>
    <arm_group_label>bupivacaine saline group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  American society of anesthesiologists physical status class ||or |||.

          -  Patients scheduled for elective thoracotomy.

        Exclusion Criteria:

          -  Pneumonectomy, decortication, pleural biopsy.

          -  Additional chest wall resection.

          -  Emergency surgery.

          -  Central and peripheral neuropathies.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamed Abdulatif, MD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor of anesthesia, surgical intensive care and pain management cairo university</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kasr Alainy Hospital Cairo University</name>
      <address>
        <city>Giza</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <results_reference>
    <citation>Marhofer D, Kettner SC, Marhofer P, Pils S, Weber M, Zeitlinger M. Dexmedetomidine as an adjuvant to ropivacaine prolongs peripheral nerve block: a volunteer study. Br J Anaesth. 2013 Mar;110(3):438-42. doi: 10.1093/bja/aes400. Epub 2012 Nov 15.</citation>
    <PMID>23161360</PMID>
  </results_reference>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 15, 2015</study_first_submitted>
  <study_first_submitted_qc>March 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2015</study_first_posted>
  <last_update_submitted>January 30, 2016</last_update_submitted>
  <last_update_submitted_qc>January 30, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Professor Mohamed Abdulatif Mohamed</investigator_full_name>
    <investigator_title>Professor of Anesthesiology &amp; Surgical Intensive Care, Faculity of Medicine</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

